Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
2019 ◽
Vol 127
◽
pp. 44-52
◽
Christos Chouaid
◽
Lionel Bensimon
◽
Emilie Clay
◽
Aurélie Millier
◽
Laurie Levy-Bachelot
◽
...
2020 ◽
Vol 146
◽
pp. 385-386
Min Huang
◽
Ralph P. Insinga
◽
Thomas Burke
◽
Ying Zhang
◽
Gilberto de Lima Lopes
J. Verma
◽
D. Verma
◽
A. Maria
2016 ◽
Vol 19
(7)
◽
pp. A888-A889
F Wen
◽
H Zheng
◽
P Zhang
◽
DW Hutton
◽
Q Li
2021 ◽
Vol Volume 13
◽
pp. 4263-4270
Longfeng Zhang
◽
Na Li
◽
Maobai Liu
◽
Bin Zheng
◽
Zhijuan Wu
◽
...
C. Chouaid
◽
L. Bensimon
◽
E. Clay
◽
A. Millier
◽
L. Lévy-Bachelot
◽
...
J. Verma
◽
D. Verma
◽
A. Maria
2020 ◽
pp. ejhpharm-2020-002208
Yuan Jiang
◽
Xingwei Wang
2020 ◽
Vol 23
◽
pp. S53-S54
J. Verma
◽
D. Verma
◽
A. Maria
2019 ◽
Vol 138
◽
pp. 88-94
◽
Longjiang She
◽
Huabin Hu
◽
Mengting Liao
◽
Xuefeng Xia
◽
Yin Shi
◽
...
Close
Export Citation Format
Close
Share Document
Close